The Medical Letter on Drugs and Therapeutics
Biktarvy - Another INSTI-Based Combination for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Biktarvy (Gilead), a once-daily, fixed-dose combination of bictegravir, a new integrase strand transfer inhibitor (INSTI), and the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide (TAF), for treatment of HIV-1 infection in adults. The new combination is indicated for use in patients who are antiretroviral-naive or who have been virologically suppressed on a stable antiretroviral regimen for ≥3 months with no history of treatment failure and no known substitutions associated with resistance to any component of the combination.

Bictegravir is the fourth INSTI to become available in the US. Emtricitabine and TAF are also available together as Descovy1 and in fixed-dose combinations with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Odefsey) and with the INSTI elvitegravir and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Biktarvy - Another INSTI-Based Combination for HIV
Article code: 1553b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian